Arkolith/Insider Trading/LGND/Form 4

Haas Jason

DirectorLIGAND PHARMACEUTICALS INC (LGND) · full profile →Form 4 · filed Jun 16, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.7M
Net Open-Market Flow
-$1.7M
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 12, 2026Option exercise(M)3K$51.56$155K10K
Jun 12, 2026Option exercise(M)1K$51.56$52K11K
Jun 12, 2026Sell(S)3K$255.01$765K8K
Jun 12, 2026Sell(S)3K$256.08$886K5K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 12, 2026Option exercise(M)3K—$07K
Jun 12, 2026Option exercise(M)1K—$06K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002001011-26-000104) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML